The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...

A new study from Cedars-Sinai Cancer reveals a potential way to overcome tumor resistance to a common chemotherapy drug ...

Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of ...

Cisplatin and carboplatin -- which have been approved for more than 30 years -- are widely used to treat a variety of cancers, including lung, head and neck, breast, bladder, ovarian, uterine, and ...

Cisplatin, a widely used anticancer drug, has been used in combination therapies but its use is limited by severe side effects, including renal toxicity, highlighting the need for safer and more ...

The chemotherapy drug cisplatin is widely used to treat many cancers, especially in children, but around 60% of children ...

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck squamous cell carcinoma undergoing radiotherapy with contraindications to ...

PEDMARQSI ® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children ...

Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...